Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Disease (R01 Clinical Trial Not Allowed)

The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting research applications focused on preclinical development of lead candidate vaccines to prevent Mycobacterium tuberculosis (Mtb) infection and/or disease, and to increase the clinical pipeline of viable vaccine candidates. The applications should utilize the R01 activity code and are not being solicited at this time. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. • The NIAID intends to publish a Notice of Funding Opportunity (NOFO) for this research. • The NOFO will utilize the R01 activity code. • Applications are not being solicited at this time. • Collaborative investigations will be encouraged. • Investigators with expertise and insights into this area of tuberculosis research are encouraged to begin to consider applying for this new NOFO.